Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 11.27% since last year same period to $278.63Mn in the Q3 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 5.32% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 119.07% since last year same period to $71.78Mn in the Q3 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 169.18% jump in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin jumped 96.88% since last year same period to 25.76% in the Q3 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 155.59% jump in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.14 - a 3.07% jump from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.14.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Acadia Pharmaceuticals Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.